Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • 8 July 2010

    India is becoming big pharma's favorite hub

    New Jersey may still be America's medicine chest, but India is fast becoming the world's medicine plant. As big pharma turns to outsourcing to shed costs. India's homegrown pharma industry turns towards world's generic medicines, the subcontinent's drug output is growing fast with 13 percent growth expected this year.

    [adsense:336x280:8701650588]

  • 8 July 2010
    Natalizumab Improves Language Processing in Patients With Multiple Sclerosis

    Treatment with natalizumab (Tysabri, Biogen Idec and Elan) leads to improved language processing and retrieval of newly learned verbal material in patients with multiple sclerosis (MS), according to research presented here at the Consortium of Multiple Sclerosis Centers 24th Annual Conference and the Third Joint Meeting of Americas Committee for Treatment and Research in Multiple Sclerosis.

  • 8 July 2010
    IPC to add monographs of radiopharmaceuticals in Indian Pharmacopoeia soon

    The Indian Pharmacopoeia Commission (IPC) has initiated efforts to include radiopharmaceuticals, used in the field of nuclear medicine, as tracers in the diagnosis and treatment of various diseases including cancer, in the Indian Pharmacopoeia for the first time.

  • 7 July 2010
    FDA Clears Liquid-Cooled Fiber for Benign Prostatic Hyperplasia

    The US Food and Drug Administration (FDA) has granted 510(k) clearance for a liquid-cooled fiber (MoXy; American Medical Systems) to be used with the company's recently launched 180-watt laser system (GreenLight Xcelerated Performance) for the treatment of benign prostatic hyperplasia.

  • 7 July 2010
    Oral Nicorandil Greatly Lowers Risk for Death in Hemodialysis Patients

    In a study of hemodialysis patients without angiographic evidence of obstructive coronary artery disease, oral nicorandil lowered the risk for cardiac death by more than 85%. Coronary artery disease is one of the leading causes of death in patients on hemodialysis, and even hemodialysis patients without significant coronary lesions are at elevated risk for cardiac death.

  • 6 July 2010
    Leucine-rich, glioma-inactivated 1{LGI1} Identified as Autoantigen Associated With Limbic Encephalitis

    Researchers have identified LGI1 (leucine-rich, glioma-inactivated 1) rather than voltage-gated potassium channels as the autoantigen associated with limbic encephalitis, a finding that may change diagnosis and classification of the disorder.

  • 6 July 2010
    Indian regulator GEAC approves 17 Bt crops for trials

    Even as the moratorium announced by Environment Ministry of India against Bt brinjal in February 2010 continues, the biotech regulator has approved field trials of 17 new genetically modified (GM) crops in the country, bringing smiles to the BioAgri industry and frown on the faces of anti-GM activists.

  • 6 July 2010
    FICCI, DOP to organize National Convention on Biopharma in India

    Considering the fact that India is a significant player in the global biopharmaceutical industry, the Federation of Chamber of Commerce of India (FICCI) and the Department of Pharmaceuticals (DOP), Government of India, are all set to organize a one-day “National Convention on Biopharma” on July 12, 2010, at Federation House, New Delhi.

    [adsense:336x280:8701650588]

  • 6 July 2010
    Atorvastatin Beats Rosuvastatin in Protecting Kidneys in Diabetic and Nondiabetic Patients

    July 2, 2010 (Munich, Germany) — Results of 2 related trials investigating the effects of statins on urinary protein excretion and kidney function found atorvastatin (ATV) protective and rosuvastatin (RSV) unprotective, and possibly harmful, in diabetic and nondiabetic patients.

  • 6 July 2010
    Study says normal adult blood can generate pluripotent stem cells

    In findings likely to make it easier and faster for stem cell biologists to generate patient-specific embryonic-like stem cells, researchers at Children's Hospital Boston have reprogrammed adult blood cells into induced pluripotent stem (iPS) cells.

Subscribe to Pharma News